THE VITATEX iCTC PLATFORM HAS BEEN ACQUIRED
BY APPLIED DNA SCIENCES.
We continue to offer products that analyze Invasive Circulating Tumor Cells (iCTCs) in standard patient blood samples.
Circulating Tumor Cell Capture and Isolation Technology
This innovative solution isolates Invasive Circulating Tumor Cells (iCTCs) from standard patient blood samples, and helps identify metastatic cells often before the primary tumors are visible to other diagnostic technologies when preventive care for impending cancer is still an option.
This past year, our collaborator Tyme Technologies, Inc. (NASDAQ: TYME) reported, for its Phase II trial using SM-88 to treat recurrent prostate cancer, that reductions in CTC counts may be a more informative indicator of benefit than changes in PSA.